The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

Regeneron Pharmaceuticals has reported encouraging results from the Phase I/II LINKER-MM1 clinical trial of its investigational bispecific antibody, linvoseltamab, in patients with relapsed ...

Regeneron Pharmaceuticals ... across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines ...

Regeneron said it will share updates on enrolment and regulatory timelines later this year and is working closely with the FDA. Odronextamab is a CD20×CD3 bispecific antibody that facilitates ...

Its incidence varies by bispecific antibodies and disease subtype ... Bristol Myers Squibb (BMS), Janssen, Takeda, AbbVie, Regeneron, and Sanofi; and advisory board membership with Pfizer and Sanofi.

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape ... and common LC, the 1st symmetric format, the discovery that natural human IgG4 is bispecific ...

Regeneron Pharmaceuticals ... uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G.

Regeneron also resubmitted the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma, to the FDA. The EC also approved Kevzara (sarilumab) for the ...